EUVIMEDEUVIMED entdecken
Crossref

Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma

Georgina V Long iD, Muhammad A Khattak, Helen J Gogas, Dirk Schadendorf iD, Ana Arance, Matteo S Carlino, Piotr Rutkowski, Gareth Rivalland, Antoni Ribas, Janice M Mehnert, Patrick A Ott, Reinhard Dummer und 18 weitere

New England Journal of Medicine · 11.11.2026

DOI: 10.1056/nejmoa2609762 ↗

Kurz gefasst

Fachartikel in der Zeitschrift New England Journal of Medicine, online erschienen am 11.11.2026. Verfasst von Georgina V Long und 29 weiteren Autor:innen. Beteiligte Einrichtung: Melanoma Institute Australia, Sydney. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Merck, Moderna.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Melanoma Institute Australia, Sydney.
  • University of Sydney, Sydney.
  • Royal North Shore Hospital, Sydney.
  • Mater Hospital, Sydney.
  • One Clinical Research, Perth, WA, Australia.
  • Edith Cowan University, Perth, WA, Australia.

ORCID-Profile: Georgina V Long, Dirk Schadendorf, Paolo A Ascierto

Förderung

  • Merck
  • Moderna

Zitieren

APA

Long, G. V., Khattak, M. A., Gogas, H. J., Schadendorf, D., Arance, A., Carlino, M. S., Rutkowski, P., Rivalland, G., Ribas, A., Mehnert, J. M., Ott, P. A., Dummer, R., Queirolo, P., Gebhardt, C., Dutriaux, C., Rojas, C., Chen, Y., Tachiki, L. M., Shapira-Frommer, R., …, & INTerpath-001 Investigators (2026). Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2609762

Vancouver

Long GV, Khattak MA, Gogas HJ, Schadendorf D, Arance A, Carlino MS, et al. Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma. New England Journal of Medicine. 2026. doi:10.1056/nejmoa2609762

BibTeX
@article{Long2026,
  author = {Long, Georgina V and Khattak, Muhammad A and Gogas, Helen J and Schadendorf, Dirk and Arance, Ana and Carlino, Matteo S and Rutkowski, Piotr and Rivalland, Gareth and Ribas, Antoni and Mehnert, Janice M and Ott, Patrick A and Dummer, Reinhard and Queirolo, Paola and Gebhardt, Christoffer and Dutriaux, Caroline and Rojas, Carlos and Chen, Yuanbin and Tachiki, Lisa M and Shapira-Frommer, Ronnie and Bechter, Oliver and Sullivan, Ryan J and Eggermont, Alexander M M and Ojalvo, Laureen S and Brown, Michelle and Zhang, Jinchun and Grebennik, Dmitri O and Fukunaga-Kalabis, Mizuho and Ascierto, Paolo A and Del Vecchio, Michele and INTerpath-001 Investigators, INTerpath-001 Investigators},
  title = {Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma},
  journal = {New England Journal of Medicine},
  year = {2026},
  doi = {10.1056/nejmoa2609762}
}
Kostenlos starten →